Wuhan YZY Biopharma Co Ltd

HKSE 2496.HK

Wuhan YZY Biopharma Co Ltd Price to Sales Ratio (P/S) on January 10, 2025: 114.11

Wuhan YZY Biopharma Co Ltd Price to Sales Ratio (P/S) is 114.11 on January 10, 2025, a -9.92% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Wuhan YZY Biopharma Co Ltd 52-week high Price to Sales Ratio (P/S) is 127.97 on February 20, 2024, which is 12.15% above the current Price to Sales Ratio (P/S).
  • Wuhan YZY Biopharma Co Ltd 52-week low Price to Sales Ratio (P/S) is 55.29 on December 12, 2024, which is -51.55% below the current Price to Sales Ratio (P/S).
  • Wuhan YZY Biopharma Co Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 100.55.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
HKSE: 2496.HK

Wuhan YZY Biopharma Co Ltd

CEO Dr. Pengfei Zhou / Ph.D., M.D.
IPO Date Sept. 26, 2023
Location China
Headquarters Building C2-1, Optics Valley Biocity
Employees 114
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.

StockViz Staff

January 15, 2025

Any question? Send us an email